Therachon expands rare disease pipeline with acquisition

9 October 2018

Swiss rare diseases focused biotech Therachon today announced the acquisition of Canada-based GLyPharma Therapeutic for an undisclosed amount.

This transformational deal marks Therachon's evolution to a multi-asset rare disease company by adding apraglutide (FE 203799), a next-generation synthetic GLP-2 analog targeting short bowel syndrome (SBS) and other devastating rare gastrointestinal diseases. The transaction comes on the heels of a $60 million mezzanine financing led by Novo Holdings.

According to the latest report published by Credence Research, “ Short Bowel Syndrome Market the market was valued at $315.1 million in 2016, and is expected to reach $ 2.9 billion by 2025, expanding at a compound annual growth rate (CAGR) of 27.5% from 2017 to 2025.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK